SLBT logo

SL SCIENCE HOLDING LTD

SLBTNASDAQ
πŸ† #2401 by market capUS Equity
$1.70β–Ό $0.12 (βˆ’7.10%)
πŸŒ™ After hours$1.66β–Ό 2.35%Regular close Β· extended-hours price shown
πŸ””
Track SLBT
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 7.1%
7dβ–² 10.4%
14dβ–Ό 6.1%
30dβ–Ό 37.6%
ytdβ–Ό 83.9%
1yβ–Ό 83.4%
🏦Market Cap
$953M
Small Cap
πŸ“ˆRevenue Growth (YoY)
-34.7%
Declining
πŸ“ŠGross Margin
35.3%
Healthy
πŸ’΅FCF Margin
-101.5%
Thin
βš–οΈP/S Ratio
433.9x
Expensive
Otter Score
68
Fair

Trading Snapshot

Day Range
$1.68 – $1.73
52-Week Range
$1.42 – $14.50
Volume
$3.20B
Avg Volume
$2.90B
Shares Outstanding
560.8M
Next Earnings
Nov 8, 2026

Fundamentals Snapshot

Annual Revenue
$2M
Last Q Revenue
$525,874
P/E Ratio
0.0
P/S Ratio
433.9x
EPS (TTM)
$0.00
Dividend Yield
0.00%

Why Investors Own SLBT

  • βœ“High-growth profile β€” revenue up +37.5% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 51% gross margin and 17% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

SLBT logo

SL SCIENCE HOLDING LTD

SLBT
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$2Mβ–Ό βˆ’34.7% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
35.3%β–Ό βˆ’38.6% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$4Mβ–² +220.8% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$2Mβ–Ό βˆ’919.1% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$1Mβ–Ό βˆ’$3M YoY
StockOtter Β· stockotter.space

About SL SCIENCE HOLDING LTD

Horizon Space Acquisition II Corp. aims to achieve strategic business combinations with other companies. This objective can be fulfilled through various transactional structures, including mergers, exchanges of shares, acquisitions of assets, direct purchases of stock, recapitalizations, or other forms of corporate reorganization. The firm was founded in 2023 and maintains its headquarters in New York, New York.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Fair
68/100

Analyst Price Target

β“˜
Average Target
$1.90
β–² +11.9% Upside
High Target$2.20
Low Target$1.70
Based on 23 analysts

Latest News & Updates

GlobeNewsWireΒ·6d ago

SL Science Presents Preclinical Data at the 85th Annual Meeting of the Japanese Cancer Association Showing Ξ³Ξ΄ T Cells Target Chemotherapy-Resistant Glioblastoma

New findings highlight the therapy's ability to preferentially destroy MGMT-positive tumor cells, the specific population that survives standard treatments and drives disease recurrence.

Seeking AlphaΒ·14d ago

SL Science: A $1.15 Billion Valuation Built On Preclinical Promises

SL Science Holding Limited is rated Sell due to an unsustainable $1.15B valuation built on a strictly preclinical pipeline. SLBT's flagship Gamma Delta T cell therapy targets aggressive solid tumors but has not entered h

GlobeNewsWireΒ·28d ago

SL Science Holding Limited Rings Nasdaq Bell, Capping an Active First Quarter as a Publicly Traded Company

NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- SL Science Holding Limited (β€œSL Science” or the β€œCompany”) (NASDAQ: SLBT), a Taiwan-headquartered biomedical company specializing in developing innovative cellular and gene th

GlobeNewsWireΒ·Aug 27

SL Science Highlights New FDA Drug Master File for GDT Cell-Derived Exosomes, Expanding the Regulatory Foundation of its Platform

TAIPEI, Taiwan, Aug. 27, 2026 (GLOBE NEWSWIRE) -- SL Science Holding Limited (β€œSL Science” or the β€œCompany”) (NASDAQ: SLBT), a Taiwan-headquartered biomedical company specializing in innovative cellular and gene therapie

GlobeNewsWireΒ·Aug 11

SL Science Leadership Co-Authors Peer-Reviewed Framework for Clinical Development of Ξ³Ξ΄ T Cell Therapy in Glioblastoma

TAIPEI, Taiwan, Aug. 11, 2026 (GLOBE NEWSWIRE) -- SL Science Holding Limited (β€œSL Science” or the β€œCompany”) (Nasdaq: SLBT), a Taiwan-headquartered biomedical company specializing in developing innovative cellular and ge

GlobeNewsWireΒ·Jul 17

SL Science Announces Successful Exhibition of Breakthrough Brain Cancer Therapy Research at the 2026 World Congress of Basic and Clinical Pharmacology

Joint presentation with Taipei Medical University, JY BioMed, and HeXun Biosciences highlighted the power of gamma delta (Ξ³Ξ΄) T cells in eliminating glioblastoma in preclinical studies.